359 related articles for article (PubMed ID: 25722303)
1. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
Yao D; Gu P; Wang Y; Luo W; Chi H; Ge J; Qian Y
Biochem Cell Biol; 2018 Jun; 96(3):317-325. PubMed ID: 29040814
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
[TBL] [Abstract][Full Text] [Related]
4. Modulation of miR-21 signaling by MPS1 in human glioblastoma.
Maachani UB; Tandle A; Shankavaram U; Kramp T; Camphausen K
Oncotarget; 2016 Aug; 7(33):52912-52927. PubMed ID: 25991676
[TBL] [Abstract][Full Text] [Related]
5. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
6. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
8. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
[TBL] [Abstract][Full Text] [Related]
9. MPS1 kinase as a potential therapeutic target in medulloblastoma.
Alimova I; Ng J; Harris P; Birks D; Donson A; Taylor MD; Foreman NK; Venkataraman S; Vibhakar R
Oncol Rep; 2016 Nov; 36(5):2633-2640. PubMed ID: 27633003
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
Tandle AT; Kramp T; Kil WJ; Halthore A; Gehlhaus K; Shankavaram U; Tofilon PJ; Caplen NJ; Camphausen K
Eur J Cancer; 2013 Sep; 49(14):3020-8. PubMed ID: 23790466
[TBL] [Abstract][Full Text] [Related]
11. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
[TBL] [Abstract][Full Text] [Related]
12. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.
Tannous BA; Kerami M; Van der Stoop PM; Kwiatkowski N; Wang J; Zhou W; Kessler AF; Lewandrowski G; Hiddingh L; Sol N; Lagerweij T; Wedekind L; Niers JM; Barazas M; Nilsson RJ; Geerts D; De Witt Hamer PC; Hagemann C; Vandertop WP; Van Tellingen O; Noske DP; Gray NS; Würdinger T
J Natl Cancer Inst; 2013 Sep; 105(17):1322-31. PubMed ID: 23940287
[TBL] [Abstract][Full Text] [Related]
13. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
[TBL] [Abstract][Full Text] [Related]
14. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
15. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.
Colombo R; Caldarelli M; Mennecozzi M; Giorgini ML; Sola F; Cappella P; Perrera C; Depaolini SR; Rusconi L; Cucchi U; Avanzi N; Bertrand JA; Bossi RT; Pesenti E; Galvani A; Isacchi A; Colotta F; Donati D; Moll J
Cancer Res; 2010 Dec; 70(24):10255-64. PubMed ID: 21159646
[TBL] [Abstract][Full Text] [Related]
16. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
[TBL] [Abstract][Full Text] [Related]
17. Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells.
Waenphimai O; Mahalapbutr P; Vaeteewoottacharn K; Wongkham S; Sawanyawisuth K
Eur J Pharmacol; 2022 May; 922():174899. PubMed ID: 35337815
[TBL] [Abstract][Full Text] [Related]
18. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
19. Microenvironmental regulation of glioblastoma radioresponse.
Jamal M; Rath BH; Williams ES; Camphausen K; Tofilon PJ
Clin Cancer Res; 2010 Dec; 16(24):6049-59. PubMed ID: 21037023
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
Faisal A; Mak GWY; Gurden MD; Xavier CPR; Anderhub SJ; Innocenti P; Westwood IM; Naud S; Hayes A; Box G; Valenti MR; De Haven Brandon AK; O'Fee L; Schmitt J; Woodward HL; Burke R; vanMontfort RLM; Blagg J; Raynaud FI; Eccles SA; Hoelder S; Linardopoulos S
Br J Cancer; 2017 Apr; 116(9):1166-1176. PubMed ID: 28334731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
